🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Dupilumab (blinded)

    Regeneron UK Limited

    Eosinophilic Gastritis

    phase 2 small molecule completed

    1 trial

  2. Dupilumab 300Mg Solution for Injection

    Regeneron UK Limited

    Pruritus

    phase 2 small molecule completed

    1 trial

  3. Dupixent®

    Regeneron UK Limited

    Allergic Rhinoconjunctivitis

    phase 2 mab completed

    1 trial

  4. Durability of protection after single immunisation with genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites – a follow-up, controlled human malaria rechallenge study

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  5. Durvalumab

    United Therapeutics Europe Ltd

    Stage IB Hepatocellular Carcinoma AJCC v8

    phase 2 mab active

    1 trial

  6. Durvalumab + Oleclumab

    MedImmune

    Stage III Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  7. EBV-TCR-T (YT-E001) cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 mab active

    1 trial

  8. EDG-5506, EDG-5506

    Edgewise Therapeutics

    Becker Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  9. EDG-7500

    Edgewise Therapeutics

    Hypertrophic Cardiomyopathy

    phase 2 small molecule active

    1 trial

  10. EDIT-101

    Editas Medicine

    Leber Congenital Amaurosis 10

    phase 2 small molecule active

    1 trial

  11. EFAVIRENZ

    The George Institute

    Type C Niemann-Pick Disease

    phase 2 small molecule active

    1 trial

  12. EG-70 (phase 1)

    Shanghai Antengene Corporation Limited

    Superficial Bladder Cancer

    phase 2 small molecule active

    1 trial

  13. EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816

    Novartis Pharmaceuticals

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  14. EGFR Antibody

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  15. ELACESTRANT

    Fondazione Telethon ETS

    Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)

    phase 2 small molecule active

    1 trial

  16. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  17. ELX-02

    Eloxx Pharmaceuticals

    Genetic Disease

    phase 2 small molecule terminated

    2 trials

  18. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  19. ENDORET-PRGF

    The George Institute

    glaucoma

    phase 2 small molecule active

    1 trial

  20. ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  21. EPLERENONE

    The George Institute

    Heart failure with reduced ejection fraction in combination with severe chronic kidney disease

    phase 2 small molecule active

    1 trial

  22. ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, MELPHALAN, VINCRISTINE TEVA 1 mg/ml, solution injectable, ALKERAN 50 mg poudre et solvant pour solution pour perfusion Melphalan

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  23. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  24. EXENATIDE

    Disc Medicine

    Gestational diabetes

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources